Multimodal Imaging of a Transcatheter Aortic Valve Implantation Within an Isolated Heart  by Quill, Jason L. et al.
J A C C : C A R D I O V A S C U L A R I M A G I N G V O L . 4 , N O . 1 0 , 2 0 1 1
© 2 0 1 1 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 8 X / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . D O I : 1 0 . 1 0 1 6 / j . j c m g . 2 0 1 1 . 0 2 . 0 2 5I M A G I N G V I G N E T T E
Multimodal Imaging of a Transcatheter Aortic
Valve Implantation Within an Isolated Heart
Jason L. Quill, PHD,* Alexander J. Hill, PHD,* Ana R. Menk, BS,* Brian T. McHenry, MS,*
Paul A. Iaizzo, PHD†
NOVEL IMAGING OF FUNCT IONAL CARDIAC ANATOMY is possible in isolated
heart preparations when a clear perfusate is used; which, in turn, provides important insights into the
device-tissue interface of implanted devices such as transcatheter valves. The implantation of a transcatheter
aortic valve (TAV) (CoreValve System, Medtronic, Inc., Mounds View, Minnesota) within an isolated human
heart was performed using echocardiography, ﬂuoroscopy, and direct visualization to compare imaging
modalities for better understanding of the implantation procedure (Fig. 1, Online Video 1).
Figure 1. CoreValve Deployment Sequence
The implantation of a transcatheter aortic valve within an isolated human heart is shown using simultaneously captured endoscopic
footage from the aorta, left ventricle (LV), echocardiography (Echo), and ﬂuoroscopy (Fluoro). This heart had an intrinsic rhythm and
could sustain function in a 4-chamber working mode, with baseline systolic and diastolic LV pressures of 83/12 mm Hg. The dimensions
of the aortic root at the basal attachment of the valve leaﬂets were 25  29 mm, as measured by echocardiography. A 29 mm Cor-
eValve prosthesis (Medtronic, Inc.) was chosen for implantation. Initially, a guidewire was positioned retrograde across the native aortic
valve and into the LV. The delivery system was then placed over the guidewire and advanced until the transcatheter aortic valve (TAV)
was properly positioned (Delivery System Positioned). The delivery system was unsheathed until the inﬂow portion of the TAV frame was
partially expanded, and any required minor adjustments to location were made (Early Deployment). The delivery system was then
unsheathed until the leaﬂets of the TAV were functioning and an angiography was performed to assess device position, function, and
coronary ﬂow (Late Deployment). The TAV was then fully unsheathed and deployed (Final Deployment). A ﬁnal angiography on the
deployed TAV was performed and endoscopic images were obtained of the functioning valve. The entire procedure can be viewed in
Online Video 1. Continued on next page
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Transcatheter Valve Implementation Imaging
1139Endoscopic cameras (IplexFX, Olympus Corporation, Tokyo, Japan) were placed within the ascending
aorta and left ventricle of a human donor heart (LifeSource, St. Paul, Minnesota) that was deemed not
viable for transplantation. The heart was reanimated and perfused with a clear Krebs-Henseleit buffer
according to previously described methodologies (1). Epicardial echo measurements were performed
using a transthoracic probe (Vivid i, GE Healthcare, Waukesha, Wisconsin). These images have
tremendous educational value for patients, clinicians, and design engineers.
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